Edition:
United Kingdom

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

2.11USD
16 Nov 2018
Change (% chg)

$-0.08 (-3.65%)
Prev Close
$2.19
Open
$2.16
Day's High
$2.25
Day's Low
$2.07
Volume
212,030
Avg. Vol
219,104
52-wk High
$6.19
52-wk Low
$1.55

Latest Key Developments (Source: Significant Developments)

Agenus Q2 Loss Per Share $0.24
Thursday, 9 Aug 2018 

Agenus Inc ::AGENUS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.24.Q2 REVENUE $16 MILLION.  Full Article

Agenus Inc Says Terminated Controlled Equity Offering Sales Agreement With Cantor Fitzgerald & Co
Tuesday, 8 May 2018 

May 8 (Reuters) - Agenus Inc ::AGENUS INC - ON MAY 7 TERMINATED CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD & CO.AGENUS SAYS 'AT-THE-MARKET' EQUITY OFFERING FACILITY UNDER SALES AGREEMENT NO LONGER AVAILABLE FOR USE - SEC FILING.  Full Article

Agenus Q1 Loss Per Share $0.53
Monday, 7 May 2018 

Agenus Inc ::AGENUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.53.Q1 EARNINGS PER SHARE VIEW $-0.30 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS WERE $52.3 MILLION AND $60.2 MILLION AT MARCH 31, 2018 AND DECEMBER 31, 2017 RESPECTIVELY.  Full Article

Agenus Inc Files For Sale Of Up 10 Mln Shares Of Common Stock By Selling Stockholders
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Agenus Inc ::AGENUS INC FILES FOR SALE OF UP 10 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Agenus Inc ::AGENUS ANNOUNCES COMBINATION CLINICAL TRIALS OF ITS ANTI-CTLA4 (AGEN1884) & ANTI-PD1 (AGEN2034).AGENUS INC - ANNOUNCED LAUNCH OF COMBINATION TRIAL WITH ITS PROPRIETARY ANTI-CTLA4 AND ANTI-PD1 ANTIBODIES.  Full Article

Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Agenus Inc ::AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS.AGENUS INC - TRANSACTION IS COMPRISED OF $190 MILLION OF CASH PROCEEDS AT CLOSING PLUS UP TO $40 MILLION IN MILESTONE PAYMENTS.AGENUS INC - AGENUS WILL USE PART OF THE PROCEEDS TO REDEEM ITS ROYALTY BOND FROM OBERLAND, AMONG OTHERS.AGENUS INC - IN EVENT THAT CERTAIN SALES MILESTONES ARE NOT MET, AGENUS WILL OWE HCR APPROXIMATELY $26 MILLION IN 2021.  Full Article

Agenus reports Q3 loss per share $0.37
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Agenus Inc :Agenus reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.37.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Agenus Inc - ‍Cash, cash equivalents and short-term investments were $70.1 million at Sept 30, 2017 compared to $76.4 million as of Dec 31, 2016​.Agenus Inc - Qtrly revenue $3.4 million versus $4.4 mln‍​.  Full Article

Agenus files for mixed shelf of up to $250 million
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Agenus Inc :Agenus Inc files for mixed shelf of up to $250 million – SEC filing‍​.  Full Article

Venbio Select Advisor LLC reports a 5.41 pct passive stake in Agenus
Thursday, 9 Feb 2017 

Agenus Inc :Venbio Select Advisor Llc reports a 5.41 passive stake in Agenus Inc as on December 31, 2016 - sec filing.  Full Article

Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine
Tuesday, 17 Jan 2017 

Agenus Inc : Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine .Agenus says under collaboration, Agenus will supply Prophage, Merck will provide pembrolizumab and NCI and BTTC member sites will recruit patients and conduct trial.  Full Article